A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial

• Published in: Clinical nutrition (Edinburgh, Scotland) Vol. 39; no. 5; pp. 1379 - 1384
• Main Authors: Mercurio, Valentina, Pucci, Giacomo, Bosso, Giorgio, Fazio, Valeria, Battista, Francesca, Iannuzzi, Angela, Brambilla, Nadia, Vitalini, Cristina, D'Amato, Massimo, Giacovelli, Giampaolo, Vaudo, Gaetano, Schillaci, Giuseppe, Galletti, Ferruccio, Bonaduce, Domenico
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-05-2020
• Subjects: Echocardiography; Left ventricular hypertrophy; Metabolic syndrome; Nutraceutical combination; Echocardiography; Metabolic syndrome; Nutraceutical combination; Left ventricular hypertrophy
• ISSN: 0261-5614; 1532-1983
• DOI: 10.1016/j.clnu.2019.06.026

Increased left ventricular mass (LVM) is often present in metabolic syndrome (MS), also in the setting of well-controlled blood pressure (BP). Aim of the present study was to evaluate the efficacy of a nutraceutical combination of berberine, red yeast rice extract and policosanol (Armolipid Plus™, AP) in reducing LVM in patients with MS and left ventricular hypertrophy (LVH).
In this multicenter, randomized, double-blind, placebo-controlled trial, 158 patients with MS (IDF criteria) and LVH (LVM > 48 g/m2.7 in men and > 44 g/m2.7 in women), were randomized 1:1 to receive AP or placebo for 24 weeks. Reduction of LVM, regression of LVH, and changes in lipids were analysed.
One-hundred-and-forty-five patients (AP n = 74, placebo n = 71) completed the study. A significant percentage reduction in LVM was observed in AP group vs baseline (−2.7%, p < 0.0001), and compared to placebo (−4.1%, p < 0.0001), and remained significant after adjustment for age, sex, baseline systolic BP and BMI and their changes during the study period. The proportion of subjects showing LVM reduction was higher in AP group than in the placebo group (57% vs 28%, adjusted p = 0.007). Treatment with AP was associated with improvement of lipid profile.
24-week of treatment with AP is associated with a significant reduction in LVM in subjects with MS and LVH, in addition to favourable effects on lipid profile, and could represent an effective strategy aiming at reducing the associated cardiovascular risk.
The trial was registered at clinicaltrials.gov with ID NCT02295176.